| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-80755 | |||
| BSA Free | NBP1-19015SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-77288-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-430SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-06398SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2732SS | |||
| Azide and BSA Free | NBP2-80779 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | BC100-520SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-1828SS | |||
| Azide and BSA Free | NBP2-80880 | |||
![Western Blot: Glyoxalase I Antibody (Glo1a) [NBP1-19015] - Detection of GLO-1 in human cell lines. Lane 1,2 and 3: MG-63 osteosarcoma cell line (positive control), 402-91 liposarcoma cell line and 402-91 liposarcoma cell line resistant to trabectedine. Image from verified customer review.](http://images.novusbio.com/fullsize/Glyoxalase-I-Antibody-Glo1a-Western-Blot-NBP1-19015-img0007.jpg "Western Blot: Glyoxalase I Antibody (Glo1a) [NBP1-19015] - Detection of GLO-1 in human cell lines. Lane 1,2 and 3: MG-63 osteosarcoma cell line (positive control), 402-91 liposarcoma cell line and 402-91 liposarcoma cell line resistant to trabectedine. Image from verified customer review.")
![Immunocytochemistry/Immunofluorescence: Glyoxalase I Antibody (Glo1a) [NBP1-19015] - Immunostaining of human retinal endothelial cells. Immunoreactivity for hGlx-1 was detected in human retinal endothelial cells stained with Glo1a mAb using anti mouse IgG Texas Red as secondary Ab. The cells were counter stained with phalloidin (green) and DAPI (blue), nuclear stain. No reactivity was detected in control cells, stained without Go1a mAb. Figure is a representative of 3 independent experiments. Photo courtesy of Dr. Nagaraj, Case Western Reserve University.](http://images.novusbio.com/fullsize/Glyoxalase-I-Antibody-Glo1a-Immunocytochemistry-Immunofluorescence-NBP1-19015-img0004.jpg)
![Western Blot: Glyoxalase I Antibody (Glo1a) [NBP1-19015] - HeLa whole cell extracts.](http://images.novusbio.com/fullsize/Glyoxalase-I-Antibody-Glo1a-Western-Blot-NBP1-19015-img0003.jpg)
![Simple Western: Glyoxalase I Antibody (Glo1a) [NBP1-19015] - Simple Western lane view shows a specific band for GLO1 in 0.5 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230kDa separation system. * Non-specific interaction with the 230 kDa Simple Western standard may be seen with this antibody.](http://images.novusbio.com/fullsize/Glyoxalase-I-Antibody-Glo1a-Simple-Western-NBP1-19015-img0006.jpg)
![Simple Western: Glyoxalase I Antibody (Glo1a) [NBP1-19015] - Simple Western lane view shows a specific band detected for GLO1 in HeLa lysate. This experiment was performed under reducing conditions using the Wes or Sally Sue separation system 12-230kDa (or 66-440kDa).](http://images.novusbio.com/fullsize/Glyoxalase-I-Antibody-Glo1a-Simple-Western-NBP1-19015-img0005.jpg)
![Immunohistochemistry: PLAG1 Antibody (3B7) [H00005324-M02] - Detection of the FGFR1-PLAG1 & TGFBR3-PLAG1 fusion genes. a Illustration of the FGFR1-PLAG1 fusion gene. Arrows show locations of genomic break points for each of the tumors. b Expression of PLAG1 (left) & FGFR1 (right) in PLAG1 fusion-negative vs. FGFR1-PLAG1-positive tumors. Graphs show fragments per kilobase of exon per million fragments mapped (FPKM), based on RNA-seq data. ****P < 0.0001; Student’s t-test. n = 19 + 7. Horizontal lines show mean values. c Illustration of the TGFBR3-PLAG1 fusion gene. d Expression (FPKM) of PLAG1 (left) & TGFBR3 (right) in PLAG1 fusion-negative vs. TGFBR3-PLAG1-positive tumors. ***P < 0.001, ****P < 0.0001; Student’s t-test. n = 19 + 5. Horizontal lines show mean values. e Left, IHC showing TGFBR3 staining in whole tumor sections (upper panels, scale bars=5 mm) & enlargement of selected areas (lower panels, scale bars=100 μm). Right, quantification of IHC TGFBR3 levels in TGFBR3-PLAG1 positive vs. negative tumors. P (high TGFBR3) = 0.002, Fisher’s exact test. n = 5 + 34. f Poisson sample clustering based on gene expression in cohort 1, annotated by TGFBR3 IHC results Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-017-01178-z), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00005324-m02_mouse-monoclonal-plag1-antibody-3b7-310202415485128.jpg)
![Western Blot: S100A4 Antibody (1F12-1G7) [H00006275-M01] - Analysis of S100A4 expression in transfected 293T cell line by S100A4 monoclonal antibody (M01), clone 1F12-1G7.Lane 1: S100A4 transfected lysate(11.7 KDa).Lane 2: Non-transfected lysate.](http://images.novusbio.com/fullsize/S100A4-Antibody-1F12-1G7-Western-Blot-H00006275-M01-img0011.jpg "Western Blot: S100A4 Antibody (1F12-1G7) [H00006275-M01] - Analysis of S100A4 expression in transfected 293T cell line by S100A4 monoclonal antibody (M01), clone 1F12-1G7.Lane 1: S100A4 transfected lysate(11.7 KDa).Lane 2: Non-transfected lysate.")
![Immunocytochemistry/Immunofluorescence: S100A4 Antibody (1F12-1G7) [H00006275-M01] - Analysis of monoclonal antibody to S100A4 on HeLa cell. Antibody concentration 15 ug/ml.](http://images.novusbio.com/fullsize/S100A4-Antibody-1F12-1G7-Immunocytochemistry-Immunofluorescence-H00006275-M01-img0007.jpg)
![Western Blot: S100A4 Antibody (1F12-1G7) [H00006275-M01] - S100A4 expression in NIH/3T3 ( Cat # L018V1).](http://images.novusbio.com/fullsize/S100A4-Antibody-1F12-1G7-Western-Blot-H00006275-M01-img0001.jpg)
![Western Blot: S100A4 Antibody (1F12-1G7) [H00006275-M01] - S100A4 monoclonal antibody (M01), clone 1F12-1G7 Analysis of S100A4 expression in Hela.](http://images.novusbio.com/fullsize/S100A4-Antibody-1F12-1G7-Western-Blot-H00006275-M01-img0009.jpg)
![Western Blot: S100A4 Antibody (1F12-1G7) [H00006275-M01] - S100A4 monoclonal antibody (M01), clone 1F12-1G7. Analysis of S100A4 expression in Raw 264.7.](http://images.novusbio.com/fullsize/S100A4-Antibody-1F12-1G7-Western-Blot-H00006275-M01-img0010.jpg)
![ELISA: S100A4 Antibody (1F12-1G7) [H00006275-M01] - Detection limit for recombinant GST tagged S100A4 is approximately 0.1ng/ml as a capture antibody.](http://images.novusbio.com/fullsize/S100A4-Antibody-1F12-1G7-ELISA-H00006275-M01-img0012.jpg)
![Western Blot: IFN-beta Antibody [NBP1-77288] - Independent Antibody Validation (IAV) via Protein Expression Profile in Human and Mouse Cell Lines. Loading: 15 ug of lysates per lane. Antibodies: IFN-beta NBP1-77288 (4 ug/mL), IFN-beta from Company B, (5 ug/mL) and beta-actin NBP1-76692 (1 ug/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/IFN-beta-Antibody-Western-Blot-NBP1-77288-img0008.jpg "<b>Independent Antibodies Validation. </b>Western Blot: IFN-beta Antibody [NBP1-77288] - Independent Antibody Validation (IAV) via Protein Expression Profile in Human and Mouse Cell Lines. Loading: 15 ug of lysates per lane. Antibodies: IFN-beta NBP1-77288 (4 ug/mL), IFN-beta from Company B, (5 ug/mL) and beta-actin NBP1-76692 (1 ug/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.")
![<b>Independent Antibodies Validation. </b>Immunohistochemistry-Paraffin: IFN-beta Antibody [NBP1-77288] - Analysis of paraffin-embedded human liver tissue using anti-IFN-beta at 5 ug/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.](http://images.novusbio.com/fullsize/IFN-beta-Antibody-Immunohistochemistry-Paraffin-NBP1-77288-img0004.jpg)
![<b>Expression of Tagged Proteins Validation. </b>Western Blot: IFN-beta Antibody [NBP1-77288] - Validation in Multiple Tissues and Recombinant ProteinLoading: 15 ug of lysates per lane.Antibodies: IFN-beta (4 ug/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/IFN-beta-Antibody-Western-Blot-NBP1-77288-img0005.jpg)
![Western Blot: IFN-beta Antibody [NBP1-77288] - Loading: 15 ug of lysates per lane.Antibodies: IFN-beta (4 ug/mL), IFN-beta , (5 ug/mL) and beta-actin (1 ug/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/IFN-beta-Antibody-Western-Blot-NBP1-77288-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: IFN-beta Antibody [NBP1-77288] - analysis of 4% paraformaldehyde-fixed mouse liver tissue labeling IFN-beta with 4243 at 20 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).](http://images.novusbio.com/fullsize/IFN-beta-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-77288-img0001.jpg)
![Immunohistochemistry-Paraffin: IFN-beta Antibody [NBP1-77288] - Analysis of paraffin-embedded human liver tissue using anti-IFN-beta antibody at 2.5 ug/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.](http://images.novusbio.com/fullsize/IFN-beta-Antibody-Immunohistochemistry-Paraffin-NBP1-77288-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: IFN-beta Antibody [NBP1-77288] - Analysis of IFN-beta Antibody on mouse N9 cell line. Dilution 1:200. Image from verified customer review.](http://images.novusbio.com/fullsize/antibody/nbp1-77288_rabbit-polyclonal-ifn-beta-antibody-immunocytochemistry-immunofluorescence-2042023134812.jpg)
![Immunocytochemistry/ Immunofluorescence: IFN-beta Antibody - BSA Free [NBP1-77288] - Validation of IFN-beta in Human Liver Cells. Immunofluorescent analysis of 4% paraformaldehyde-fixed human liver cells labeling IFN-beta with at 20 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).](http://images.novusbio.com/fullsize/nbp1-77288_rabbit-polyclonal-ifn-beta-antibody-2711202419463433.jpg)
![Western Blot: p38 [p Thr180, p Tyr182] Antibody [NB500-138] - Hela cell lysates that had been treated with UV or untreated (Control) showing specific immunolabeling of the -39 kDa p38 MAPK protein phosphorylated at Thr180/Tyr182.](http://images.novusbio.com/fullsize/p38-[p-Thr180--p-Tyr182]-Antibody-Western-Blot-NB500-138-img0005.jpg "Western Blot: p38 [p Thr180, p Tyr182] Antibody [NB500-138] - Hela cell lysates that had been treated with UV or untreated (Control) showing specific immunolabeling of the -39 kDa p38 MAPK protein phosphorylated at Thr180/Tyr182.")
![Immunohistochemistry-Paraffin: p38 [p Thr180, p Tyr182] Antibody [NB500-138] - Immunostaining of human breast cancer tissue showing p38 when phosphorylated at Thr180/Tyr182 in red.](http://images.novusbio.com/fullsize/p38-[p-Thr180-p-Tyr182]-Antibody-Immunohistochemistry-Paraffin-NB500-138-img0002.jpg)
![Western Blot: p38 [p Thr180, p Tyr182] Antibody [NB500-138] - Western blot of HeLa cell lysates that had been treated with UV or untreated (Control) showing specific immunolabeling of the ~39k p38 MAPK protein phosphorylated at Thr180/Tyr182.](http://images.novusbio.com/fullsize/p38-[p-Thr180-p-Tyr182]-Antibody-Western-Blot-NB500-138-img0001.jpg)
![Western Blot: p38 alpha [p Thr180, p Tyr182] Antibody [NB500-138] - RIP2 is not essential for MAPK pathways in the early ontogenesis. (A) Immunoblot analysis of phospho-p44/42 MAPK, p44/42 MAPK, & p38 MAPK in larvae homogenate from WT & NOD1-1IS−/− zebrafish at 7 days post-fertilization (dpf). (B) Immunoblot analysis of phospho-p44/42 MAPK, p44/42 MAPK, & p38 MAPK in larvae homogenate from WT & RIP2−/− zebrafish at 7 dpf. (C) Immunoblot analysis of Atg5, p62, & LC3b in larvae homogenate from WT & NOD1-1IS−/− zebrafish at 7 dpf. (D) Immunoblot analysis of Atg5, p62, & LC3b in larvae homogenate from WT & RIP2−/− zebrafish at 7 dpf. Western blotting results were quantified using Quantity One software. Data represent the average of two independent experiments. *p < 0.05, **p < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29692779), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-138_rabbit-polyclonal-p38-alpha-p-thr180-p-tyr182-antibody-31020241534371.jpg)
![Western Blot: CIDEC Antibody [NB100-430] - Analysis of CIDEC using NB100-430 at 1:1000 dilution on 30ug HepG2 cell lysate.](http://images.novusbio.com/fullsize/CIDEC-Antibody-Western-Blot-NB100-430-img0001.jpg "Western Blot: CIDEC Antibody [NB100-430] - Analysis of CIDEC using NB100-430 at 1:1000 dilution on 30ug HepG2 cell lysate.")
![Immunohistochemistry: Glutathione Peroxidase 3/GPX3 Antibody [NBP1-06398] - GPX3 expressions in adenocarcinoma (AC). EnVision immunohistochemistry, original magnification x200. GPX3 positive reaction was mainly localized in the cytoplasm. Negative GPX3 expression in poorly differentiated AC (c), and positive GPX3 expression in well-differentiated AC (d). Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/dm/2013/187043/), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Glutathione-Peroxidase-3-GPX3-Antibody-Immunohistochemistry-NBP1-06398-img0007.jpg "Immunohistochemistry: Glutathione Peroxidase 3/GPX3 Antibody [NBP1-06398] - GPX3 expressions in adenocarcinoma (AC). EnVision immunohistochemistry, original magnification x200. GPX3 positive reaction was mainly localized in the cytoplasm. Negative GPX3 expression in poorly differentiated AC (c), and positive GPX3 expression in well-differentiated AC (d). Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/dm/2013/187043/), licensed under a CC-BY license.")
![Immunohistochemistry: Glutathione Peroxidase 3/GPX3 Antibody [NBP1-06398] - GPX3 expressions in squamous carcinomas/adenosquamous carcinomas (SC/ASC). EnVision immunohistochemistry, original magnification x200. GPX3 positive reaction was mainly localized in the cytoplasm. Negative GPX3 expression in poorly differentiated SC/ASC (c). Positive GPX3 expression in well-differentiated SC/ASC (d). Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/dm/2013/187043/), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Glutathione-Peroxidase-3-GPX3-Antibody-Immunohistochemistry-NBP1-06398-img0006.jpg)
![Western Blot: Glutathione Peroxidase 3/GPX3 Antibody [NBP1-06398] - Analysis of GPX3 in human kidney lysate.](http://images.novusbio.com/fullsize/Glutathione-Peroxidase-3-GPX3-Antibody-Western-Blot-NBP1-06398-img0002.jpg)
![Immunohistochemistry-Paraffin: Glutathione Peroxidase 3/GPX3 Antibody [NBP1-06398] - IHC analysis of formalin fixed paraffin-embedded (FFPE) human kidney using 1:200 conc. of Glutathione Peroxidase 3 antibody on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images was performed using Aperio AT2 (Leica Biosystems). Cytoplasmic staining of Glutathione Peroxidase 3 was observed. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/Glutathione-Peroxidase-3-GPX3-Antibody-Immunohistochemistry-Paraffin-NBP1-06398-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: Glutathione Peroxidase 3/GPX3 Antibody [NBP1-06398] - The GPX3 antibody was tested in HeLa cells at a 1:250 dilution against Dylight 488 (Green). Alpha-tubulin and nuclei were counterstained against Dylight 550 (Red) and DAPI blue).](http://images.novusbio.com/fullsize/Glutathione-Peroxidase-3-GPX3-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-06398-img0003.jpg)
![Immunohistochemistry: Glutathione Peroxidase 3/GPX3 Antibody [NBP1-06398] - ALDH1A3 & GPX3 expressions in squamous carcinomas/adenosquamous carcinomas (SC/ASC). EnVision immunohistochemistry, original magnification ×200. ALDH1A3 & GPX3 positive reaction was mainly localized in the cytoplasm. (a), positive ALDH1A3 expression in poorly differentiated SC/ASC. (b), negative ALDH1A3 expression in well-differentiated SC/ASC. (c), negative GPX3 expression in poorly differentiated SC/ASC. (d), positive GPX3 expression in well-differentiated SC/ASC. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24167362), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-06398_rabbit-polyclonal-glutathione-peroxidase-3-gpx3-antibody-31020241517522.jpg)
![Immunohistochemistry: Glutathione Peroxidase 3/GPX3 Antibody [NBP1-06398] - ALDH1A3 & GPX3 expressions in adenocarcinoma (AC). EnVision immunohistochemistry, original magnification ×200. ALDH1A3 & GPX3 positive reaction was mainly localized in the cytoplasm. (a), positive ALDH1A3 expression in moderately differentiated AC. (b), negative ALDH1A3 expression in well-differentiated AC. (c), negative GPX3 expression in poorly differentiated AC. (d), positive GPX3 expression in well-differentiated AC. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24167362), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-06398_rabbit-polyclonal-glutathione-peroxidase-3-gpx3-antibody-310202415291925.jpg)
![Western Blot: GPER/GPR30 Antibody [NBP1-31239] - The MW of GPR30 is estimated to be 42 kDa, but higher MW sizes have been reported due to glycosylation and interaction with other proteins. Bands are identified as glycosylated and nonglycosylated based on reports cited in the text, but could include interaction with other proteins. For each GPER western, the membrane was stripped and reprobed for b-actin as a loading control. Quantitation of GPER was evaluated by summing all immunoreactive bands and dividing by b-actin, then normalizing to HBEC2-KT in each blot. Image collected and cropped by CiteAb from the following publication (biomedcentral.com/1471-2407/12/624), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/GPER-GPR30-Antibody-Western-Blot-NBP1-31239-img0012.jpg "Western Blot: GPER/GPR30 Antibody [NBP1-31239] - The MW of GPR30 is estimated to be 42 kDa, but higher MW sizes have been reported due to glycosylation and interaction with other proteins. Bands are identified as glycosylated and nonglycosylated based on reports cited in the text, but could include interaction with other proteins. For each GPER western, the membrane was stripped and reprobed for b-actin as a loading control. Quantitation of GPER was evaluated by summing all immunoreactive bands and dividing by b-actin, then normalizing to HBEC2-KT in each blot. Image collected and cropped by CiteAb from the following publication (biomedcentral.com/1471-2407/12/624), licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: GPER/GPR30 Antibody [NBP1-31239] - Detection of GPER/GPR30 in HUVEC nucleus. Image courtesy of a product review by Dr. Subhadeep Chakrabarti of University of Alberta.](http://images.novusbio.com/fullsize/GPER-GPR30-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-31239-img0010.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: GPER/GPR30 Antibody [NBP1-31239] - A. 50 ug 293T whole cell lysate/extract. B. 50 ug whole cell lysate/extract of GFP-human GPR30-transfected 293T cells (No boiling). C. 50 ug whole cell lysate/extract of GFP-human GPR30 and GPR30 siRNA-transfected 293T cells (No boiling). 5 % SDS-PAGE GPR30 antibody ) dilution: 1:1000](http://images.novusbio.com/fullsize/GPER-GPR30-Antibody-Western-Blot-NBP1-31239-img0011.jpg)
![Western Blot: GPER/GPR30 Antibody [NBP1-31239] - AhR & GPR30 receptors are present & functional in the MCF10AT1 cells. (A) RT-qPCR analysis of AhR & GPR30 mRNA expression levels represented in arbitrary units (a.u.) in the MCF10AT1 & MCF10CA1a.cl1 cells. MCF-7 cells were used as a control. Values represent mean ± SD of three independent experiments conducted in triplicate. (B) Representative Western blot analyses from three independent experiments of AhR & GPR30 protein expression in MCF10AT1 & MCF10CA1a.cl1 cells. MCF-7 cells were used as a control. (C) XRE-luciferase activity following 8 h exposure of MCF10AT1 cells to ITE at the indicated concentrations. TCDD 10−7 M was used as a control & results were expressed as % of TCDD 10−7 M activity. ***p < 0.001 in Student t-test. (D) XRE-luciferase activity upon 8 h of exposure to ITE 10−10 M alone or in combination with GNF351 at the indicated concentrations. TCDD 10−7 M was used as a control, & results were expressed as % of TCDD 10−7 M activity. Student t-tests revealed the statistically significant differences between unexposed & exposed cells: ***p < 0.001; & between ITE & ITE+GNF351: ###p < 0.001. Values in (C,D) represent mean ± SD of three independent experiments. (E) Representative Western blot analyses from three independent experiments of the phospho-MAPK/MAPK ratio upon exposure of MCF10AT1 cells to G1 (GPR30 agonist) for the times indicated, in the presence or absence of a 2 h pre-treatment with G15 (GPR30 antagonist). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32670863), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-31239_rabbit-polyclonal-gper-gpr30-antibody-310202416171440.jpg)
![Western Blot: GPER/GPR30 Antibody [NBP1-31239] - Effects of short-term exposure of BPA, B[a]P, ITE & G1 10−10 M on AIG & MFE are inhibited by siRNA-AhR & siRNA-GPR30. Representative Western blot analysis from three independent experiments of AhR & GPR30 expression in transfected MCF10AT1 cells with (A) siRNA-AhR, (B) siRNA-GPR30 or their scrambled controls. Quantification of protein expression levels was normalized against tubulin expression. (C,D) Secondary mammospheres formation & (E,F) average number of colonies in soft agar, with the following treatments: BPA and/or B[a]P, G1, or ITE, 10−10 M. Cells were transfected with either siRNA-AhR, siRNA-GPR30 or their scrambled controls before being subjected to the treatments. Treatments were maintained throughout the course of experiments. (mean ± SD of 2 independent experiments, in triplicate). ***p < 0.001, *p < 0.05 vs. their respective unexposed; ###p < 0.001 siRNA vs. scrambled in Student t-test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32670863), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-31239_rabbit-polyclonal-gper-gpr30-antibody-310202416173515.jpg)
![Western Blot: GPER/GPR30 Antibody [NBP1-31239] - Human endothelial cells express GPR30 protein in the cell nucleus.(A) Confluent monolayers of HUVECs from 3 different cords were lysed & the protein lysates were immunoblotted for GPR30. alpha -tubulin was used as loading control. (B) HUVEC monolayers at 30–40% confluence were treated with 40 nM siRNA (control or GPR30_4) for 48 hours prior to lysis followed by immunoblotting of the cell lysates for GPR30. alpha -tubulin was used as loading control. Data shown are mean ± SEM of 4 independent experiments. ** & ## indicate p<0.01 compared to untreated & control siRNA-treated cells, respectively. (C) Confluent HUVECs grown on glass coverslips were fixed, permeabilized & immunostained with anti-GPR30 antibody. Nuclei were stained with Hoechst33342 dye. The merged image shows GPR30 (red) & nuclei (blue) in pseudocolor. Representative images from 3 independent experiments are shown. Bar, 20 µm. (D) Confluent HUVECs were lysed & fractionated into cytosolic (C) & nuclear (N) fractions prior to western blotting for eNOS, GPR30, p65, alpha -tubulin & c-Jun. A representative set of images (obtained from different membranes) from 3 independent experiments is shown. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23285008), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-31239_rabbit-polyclonal-gper-gpr30-antibody-310202416175294.jpg)
![Western Blot: GPER/GPR30 Antibody [NBP1-31239] - Effects of short-term exposure of BPA, B[a]P, ITE & G1 10−10 M on AIG & MFE are inhibited by siRNA-AhR & siRNA-GPR30. Representative Western blot analysis from three independent experiments of AhR & GPR30 expression in transfected MCF10AT1 cells with (A) siRNA-AhR, (B) siRNA-GPR30 or their scrambled controls. Quantification of protein expression levels was normalized against tubulin expression. (C,D) Secondary mammospheres formation & (E,F) average number of colonies in soft agar, with the following treatments: BPA and/or B[a]P, G1, or ITE, 10−10 M. Cells were transfected with either siRNA-AhR, siRNA-GPR30 or their scrambled controls before being subjected to the treatments. Treatments were maintained throughout the course of experiments. (mean ± SD of 2 independent experiments, in triplicate). ***p < 0.001, *p < 0.05 vs. their respective unexposed; ###p < 0.001 siRNA vs. scrambled in Student t-test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32670863), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-31239_rabbit-polyclonal-gper-gpr30-antibody-310202416173516.jpg)
![Western Blot: GPER/GPR30 Antibody [NBP1-31239] - Effects of short-term exposure of BPA, B[a]P, ITE & G1 10−10 M on AIG & MFE are inhibited by siRNA-AhR & siRNA-GPR30. Representative Western blot analysis from three independent experiments of AhR & GPR30 expression in transfected MCF10AT1 cells with (A) siRNA-AhR, (B) siRNA-GPR30 or their scrambled controls. Quantification of protein expression levels was normalized against tubulin expression. (C,D) Secondary mammospheres formation & (E,F) average number of colonies in soft agar, with the following treatments: BPA and/or B[a]P, G1, or ITE, 10−10 M. Cells were transfected with either siRNA-AhR, siRNA-GPR30 or their scrambled controls before being subjected to the treatments. Treatments were maintained throughout the course of experiments. (mean ± SD of 2 independent experiments, in triplicate). ***p < 0.001, *p < 0.05 vs. their respective unexposed; ###p < 0.001 siRNA vs. scrambled in Student t-test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32670863), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-31239_rabbit-polyclonal-gper-gpr30-antibody-310202416163721.jpg)
![Western Blot: OS9 Antibody [BC100-520] - Initial characterization of the OS-9 protein. OS-9 expression in various human cell lines. Equal protein amounts of total cell lysates were used for SDS-PAGE and subsequent Western blotting. For each cell line, two independent samples are shown. Endogenous OS-9 was detected with a polyclonal antibody raised against a peptide corresponding to amino acids 600-667 of isoform 1 of OS-9. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0019151), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/OS9-Antibody-Western-Blot-BC100-520-img0004.jpg "Western Blot: OS9 Antibody [BC100-520] - Initial characterization of the OS-9 protein. OS-9 expression in various human cell lines. Equal protein amounts of total cell lysates were used for SDS-PAGE and subsequent Western blotting. For each cell line, two independent samples are shown. Endogenous OS-9 was detected with a polyclonal antibody raised against a peptide corresponding to amino acids 600-667 of isoform 1 of OS-9. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0019151), licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: OS9 Antibody [BC100-520] - OS9 antibody was tested in HeLa cells with FITC (green). Nuclei and alpha-tubulin were counterstained with Dapi (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/OS9-Antibody-Immunocytochemistry-Immunofluorescence-BC100-520-img0002.jpg)
![Western Blot: OS9 Antibody [BC100-520] - WB analysis of OS9 in 1. A431 cell lysate, 2. HepG2 cell lysate, 3. MCF7 cell lysate and 4. 3T3 cell lysate.](http://images.novusbio.com/fullsize/OS9-Antibody-Western-Blot-BC100-520-img0001.jpg)
![Simple Western: OS9 Antibody [BC100-520] - Simple Western lane view shows a specific band for OS9 in 0.5 mg/ml of HepG2 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/OS9-Antibody-Simple-Western-BC100-520-img0003.jpg)
![Western Blot: OS9 Antibody [BC100-520] - Initial characterization of the OS-9 protein.(A) OS-9 expression in various human cell lines. Equal protein amounts of total cell lysates were used for SDS-PAGE & subsequent Western blotting. For each cell line, two independent samples are shown. Endogenous OS-9 was detected with a polyclonal antibody raised against a peptide corresponding to amino acids 600–667 of isoform 1 of OS-9. (B) Protein stability assay of endogenous OS-9. U2OS cells were treated with the translational inhibitor cycloheximide (100 µM). At indicated time points, whole cell lysates were analysed by immunoblotting. (C) Effect of hypoxia on OS-9 expression. For hypoxia, UT-7 cells were exposed to 1% O2 for 24 h prior to Western blot analysis. To determine any influence of HIF-1 alpha on OS-9 expression under normoxia, cells were incubated with the prolyl hydroxylase inhibitor DMOG (0.5 mM) for 24 h. (D) Protein interaction between OS-9 & PHD2 in vitro. For co-immunoprecipitation, U2OS cells were transiently co-transfected with the plasmids pOS-9-V5 & pPHD2-His, lysed in NP40 buffer, & subjected to immunoisolation with anti-V5 antibody recognizing OS-9 by its V5-tag. OS-9 & its associated proteins were separated by SDS-PAGE & analyzed by Western blot (lane 2). As controls, samples of untransfected (lane 1) cells or cells transfected with a single plasmid (lanes 3–4) were loaded. Representative Western blots are shown for each subfigure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21559462), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/bc100-520_rabbit-polyclonal-os9-antibody-310202415482216.jpg)
![Western Blot: OS9 Antibody [BC100-520] - Initial characterization of the OS-9 protein.(A) OS-9 expression in various human cell lines. Equal protein amounts of total cell lysates were used for SDS-PAGE & subsequent Western blotting. For each cell line, two independent samples are shown. Endogenous OS-9 was detected with a polyclonal antibody raised against a peptide corresponding to amino acids 600–667 of isoform 1 of OS-9. (B) Protein stability assay of endogenous OS-9. U2OS cells were treated with the translational inhibitor cycloheximide (100 µM). At indicated time points, whole cell lysates were analysed by immunoblotting. (C) Effect of hypoxia on OS-9 expression. For hypoxia, UT-7 cells were exposed to 1% O2 for 24 h prior to Western blot analysis. To determine any influence of HIF-1 alpha on OS-9 expression under normoxia, cells were incubated with the prolyl hydroxylase inhibitor DMOG (0.5 mM) for 24 h. (D) Protein interaction between OS-9 & PHD2 in vitro. For co-immunoprecipitation, U2OS cells were transiently co-transfected with the plasmids pOS-9-V5 & pPHD2-His, lysed in NP40 buffer, & subjected to immunoisolation with anti-V5 antibody recognizing OS-9 by its V5-tag. OS-9 & its associated proteins were separated by SDS-PAGE & analyzed by Western blot (lane 2). As controls, samples of untransfected (lane 1) cells or cells transfected with a single plasmid (lanes 3–4) were loaded. Representative Western blots are shown for each subfigure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21559462), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/bc100-520_rabbit-polyclonal-os9-antibody-310202415483621.jpg)
![Western Blot: OS9 Antibody [BC100-520] - Initial characterization of the OS-9 protein.(A) OS-9 expression in various human cell lines. Equal protein amounts of total cell lysates were used for SDS-PAGE & subsequent Western blotting. For each cell line, two independent samples are shown. Endogenous OS-9 was detected with a polyclonal antibody raised against a peptide corresponding to amino acids 600–667 of isoform 1 of OS-9. (B) Protein stability assay of endogenous OS-9. U2OS cells were treated with the translational inhibitor cycloheximide (100 µM). At indicated time points, whole cell lysates were analysed by immunoblotting. (C) Effect of hypoxia on OS-9 expression. For hypoxia, UT-7 cells were exposed to 1% O2 for 24 h prior to Western blot analysis. To determine any influence of HIF-1 alpha on OS-9 expression under normoxia, cells were incubated with the prolyl hydroxylase inhibitor DMOG (0.5 mM) for 24 h. (D) Protein interaction between OS-9 & PHD2 in vitro. For co-immunoprecipitation, U2OS cells were transiently co-transfected with the plasmids pOS-9-V5 & pPHD2-His, lysed in NP40 buffer, & subjected to immunoisolation with anti-V5 antibody recognizing OS-9 by its V5-tag. OS-9 & its associated proteins were separated by SDS-PAGE & analyzed by Western blot (lane 2). As controls, samples of untransfected (lane 1) cells or cells transfected with a single plasmid (lanes 3–4) were loaded. Representative Western blots are shown for each subfigure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21559462), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/bc100-520_rabbit-polyclonal-os9-antibody-310202415482293.jpg)
![Western Blot: OS9 Antibody [BC100-520] - Cellular localization of OS-9 & PHD2.(A) A lectin gel-shift assay was conducted to test for glycosylated proteins. Total cell lysates of U2OS cells were incubated in the presence or absence of the endoglycosidases EndoH & PNGaseF for 6 h at 37°C. Digest products were separated on a reducing 10% SDS-PAGE gel which contained concanavalin A co-polymerized in the top layer of the separating gel to retard mobility of glycosylated proteins [56]. Glycosylated OS-9 is indicated as ‘g’, deglycosylated OS-9 as ‘d’. (B) Detection of OS-9 & PHD2 in the nuclear fraction. HEK293 cells with & without transfection of the plasmid pcDNA3-OS-9 were separated into nuclear fraction (N) & postnuclear supernatant (PS), the latter containing cytoplasm & organelles. Western blot analysis included BiP, GAPDH & lamin A as typical marker proteins for the ER, the cytoplasm & the nucleus, respectively. (C) Detection of OS-9 & PHD2 in the cytoplasm. HEK293 cells were co-transfected with pcDNA3-OS-9 & pPHD2-V5. For hypoxia, cells were exposed to 3% O2 for 4 h. Cells were treated with 50 µg/ml digitonin & centrifuged to obtain a cytoplasmic (C) & an organelle fraction (O) & subjected to immunoblotting. (D) Isolation of cellular endomembranes. HEK293 cells were lysed mechanically by several passages through a 30½G needle. The postnuclear supernatant was processed further by ultra-centrifugation to separate the organelles (O) from the cytosol (C). High salt treatment (1 M KCl) of the organelle fraction produced a wash fraction (W) that contained dissociated peripheral membrane proteins. For immunoblot analysis of subcellular fractionations, cell aliquots were normalized for cell number prior to loading (B–D). Representative Western blots are shown for each subfigure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21559462), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/bc100-520_rabbit-polyclonal-os9-antibody-310202415483637.jpg)
![Western Blot: OS9 Antibody [BC100-520] - OS-9 shows no effect on regulation of HIF-1 alpha .Total cell lysates were used for SDS-PAGE & subsequent Western blotting. To generate nearly anoxic conditions, cells were exposed to an oxygen consuming chemical system or to 1% or 3% O2 for 4 h to generate hypoxia. (A) U2OS, HeLa & Hep3B cells were transiently transfected with the plasmid pOS-9-V5 48 h prior to the experiment. Lamin A & actin were used as loading controls. (B) U2OS cells were subjected to ER stress by incubation either with tunicamycin (1 µg/ml) or thapsigargin (0.5 µg/ml) for 20 h. To detect HIF-1 alpha under normoxia, cells were treated with DMOG (1 mM) for 4 h. A sample of DMSO-only treated cells was loaded to exclude unspecific side effects of the solvent. (C) U2OS cells were transduced with lentiviral construct pLKO.1-shRNA-OS-9 (shOS-9) mediating a stable knockdown of OS-9 expression. Control cells (c) were transduced with plasmid pLKO.1-puro. Representative Western blots are shown for each subfigure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21559462), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/bc100-520_rabbit-polyclonal-os9-antibody-310202415482250.jpg)
![Western Blot: Ubiquitin Antibody [NB300-129] - Analysis of HEK293 cell lysates using rabbit Ubiquitin antibody, dilution 1:5000 (Green), and mouse beta-Tubulin antibody, dilution 1:10000 (Red) used as a loading control. [1] protein standard (Red), [2] cells maintained in normal medium, [3] cells treated with proteasome inhibitor lactacystin (Lc) at 10uM for 16 hours. Lysed cells were lysed and the lysate subjected to electrophoresis on a 4-20% SDS-PAGE gel, then electrophoretically transferred to PVDF membranes. The smear detected above the 200kDa standard represents accumulations of ubiquitinated proteins in the Lc treated cells. The prominent band at ~8kDa corresponds to monoubiquitin.](http://images.novusbio.com/fullsize/Ubiquitin-Antibody-Western-Blot-NB300-129-img0009.jpg "Western Blot: Ubiquitin Antibody [NB300-129] - Analysis of HEK293 cell lysates using rabbit Ubiquitin antibody, dilution 1:5000 (Green), and mouse beta-Tubulin antibody, dilution 1:10000 (Red) used as a loading control. [1] protein standard (Red), [2] cells maintained in normal medium, [3] cells treated with proteasome inhibitor lactacystin (Lc) at 10uM for 16 hours. Lysed cells were lysed and the lysate subjected to electrophoresis on a 4-20% SDS-PAGE gel, then electrophoretically transferred to PVDF membranes. The smear detected above the 200kDa standard represents accumulations of ubiquitinated proteins in the Lc treated cells. The prominent band at ~8kDa corresponds to monoubiquitin.")
![Immunocytochemistry/Immunofluorescence: Ubiquitin Antibody [NB300-129] - Analysis of HeLa cells stained with rabbit pAb to ubiquitin, NB300-129, dilution 1:1,000 in red, and costained with chicken pAb to vimentin, dilution 1:10,000, in green. The blue is DAPI staining of nuclear DNA. [A] Control HeLa cells maintained in normal medium, [B] HeLa cells treated with 10uM of the proteasome inhibitor lactacystin (Lc) for 24 hours. Proteasomal inhibition leads to formation of strongly ubiquitin positive cytoplasmic inclusions. Note the diffuse cytoplasmic ubiquitin staining in control cells and well defined ubiquitin positive inclusions in the Lc treated cells.](http://images.novusbio.com/fullsize/Ubiquitin-Antibody-Immunocytochemistry-Immunofluorescence-NB300-129-img0008.jpg)
![Immunohistochemistry-Paraffin: Ubiquitin Antibody [NB300-129] - IHC staining of Ubiquitin in human rectal cancer using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/Ubiquitin-Antibody-Immunohistochemistry-Paraffin-NB300-129-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: Ubiquitin Antibody [NB300-129] - Immunofluorescent staining of aggresomes of mouse L-cells treated with lactacysteine, using NB300-129.](http://images.novusbio.com/fullsize/Ubiquitin-Antibody-Immunocytochemistry-Immunofluorescence-NB300-129-img0001.jpg)
![Western Blot: NKX3.1 Antibody (0361) [NB100-1828] - Analysis of NKX3.1 in HeLa cell lysate using anti-NKX3.1 antibody. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/NKX3-1-Antibody-0361-Western-Blot-NB100-1828-img0006.jpg "Western Blot: NKX3.1 Antibody (0361) [NB100-1828] - Analysis of NKX3.1 in HeLa cell lysate using anti-NKX3.1 antibody. WB image submitted by a verified customer review.")
![Immunohistochemistry-Paraffin: NKX3.1 Antibody (0361) [NB100-1828] - Staining of human chondrosarcoma tissue with NKX3.1 monoclonal antibody. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/NKX3-1-Antibody-0361-Immunohistochemistry-Paraffin-NB100-1828-img0008.jpg)
![Western Blot: Nkx3.1 Antibody (0361) [NB100-1828] - Detection of NKX3.1 in mouse testis lysate using NB 100-1828. ECL detection 1 minute.](http://images.novusbio.com/fullsize/Nkx3-1-Antibody-0361-Western-Blot-NB100-1828-img0003.jpg)
![Immunohistochemistry-Paraffin: NKX3.1 Antibody (0361) [NB100-1828] - NKX3.1 was detected in immersion fixed paraffin-embedded sections of mouse testis using Mouse Anti-Mouse NKX3.1 (0361) Monoclonal Antibody (Catalog # NB100-1828) at 1:300 for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the nuclei in sperm cells.](http://images.novusbio.com/fullsize/NKX3-1-Antibody-0361-Immunohistochemistry-Paraffin-NB100-1828-img0007.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: NKX3.1 Antibody (0361) [NB100-1828] - DWB analysis of NKX3.1 expression in the indicated cells transfected with Ri-Vector (V-Ri) or shRNAs (Ri#1/2) against NKX3.1. Image collected and cropped by CiteAb from the following publication (//www.ncbi.nlm.nih.gov/pmc/articles/PMC6895605/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NKX3-1-Antibody-0361-Knockdown-Validated-NB100-1828-img0009.jpg)
![Western Blot: NKX3.1 Antibody (0361) - BSA Free [NB100-1828] - SALL2 transcriptionally upregulates ESR1 in breast cancerARNA‐seq analysis of ESR1 mRNA levels in 9 paired pre‐tamoxifen‐treated primary breast cancer tissues & relapsed tamoxifen‐resistant breast cancer tissues.BqRT–PCR analysis of ESR1 expression in 9 paired pre‐tamoxifen‐treated primary breast cancer tissues & relapsed tamoxifen‐resistant breast cancer tissues. GAPDH was used as an internal control.C, DWB analysis of SALL2 (A) & NKX3‐1 (B) expression in the indicated cells transfected with Ri‐Vector (V‐Ri) or shRNAs (Ri#1/2) against SALL2 or NKX3‐1. alpha ‐Tubulin was used as the loading control.E, FqRT–PCR analysis of ESR1 expression in the indicated cells transfected with Ri‐Vector or shRNAs (Ri#1/2) against SALL2 or NKX3‐1.Data information: In (A), P‐values were determined by two‐tailed paired Student's t‐test. In (B), data are presented as mean ± SD, & P‐values were determined by two‐tailed unpaired Student's t‐test, n = 3. In (E & F), data are presented as mean ± SD, & P‐values were determined by one‐way ANOVA test, n = 3. *P < 0.05, **P < 0.01, ***P < 0.001, n.s., no significance. Exact P‐values are specified in Appendix Table S10.Source data are available online for this figure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31657150), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1828_mouse-monoclonal-nkx3-1-antibody-0361-310202415525249.jpg)